Does APOC3 GalNAc-conjugated ASO and siRNA therapy reduce plasma apoC3 and triglyceride levels in patients with hypertriglyceridemia?
APOC3 GalNAc-conjugated ASO and siRNA therapies effectively lower plasma apoC3 and triglycerides, with potential benefits for hepatic steatosis and cardiovascular risk.
Inhibition of apoC3 is effective across all the spectrum of hypertriglyceridemia, might have a favorable effect on hepatic steatosis (NAFLD) and the effect of apoC3 inhibition on cardiovascular risk is not limited to its effect on plasma triglycerides. APOC3 GalNAc-conjugated ASO and siRNA are both effective in decreasing plasma apoC3 and triglyceride levels.
Chebli et al. (Fri,) studied this question.